BTK and BCL2 Inhibitor Updates From ASH 2025

EP. 1: Long-Term Data From SEQUOIA Study of Zanubrutinib in CLL

December 17th 2025

Dr. Marc S. Hoffmann reveals promising 6-year results from the SEQUOIA study on zanubrutinib for chronic lymphocytic leukemia at the 2025 ASH Meeting.

EP. 2: 3-Year Data From SEQUOIA Arm D: Zanubrutinib Plus Venetoclax in Treatment-Naive, High-Risk CLL

ByMarc S. Hoffmann, MD

December 24th 2025

A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective time-limited therapy options.

EP. 3: Long-Term Follow-Up Data From ALPINE: Zanubrutinib Vs Ibrutinib in R/R CLL.

ByMarc S. Hoffmann, MD

December 31st 2025

A recent study reveals promising results for CLL patients using zanubrutinib and venetoclax, highlighting effective time-limited therapy options.

EP. 4: Sonrotoclax in R/R Mantle Cell Lymphoma After BTKi

ByMarc S. Hoffmann, MD

January 7th 2026

New findings reveal promising advancements in treating relapsed mantle cell lymphoma with BCL-2 inhibitors and novel agents, enhancing patient outcomes.